Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/09/2019 10/10/2019 10/11/2019 10/14/2019 10/15/2019 Date
290.83(c) 298.36(c) 300.77(c) 305.44(c) 303.82(c) Last
1 019 321 987 873 1 077 315 850 402 786 463 Volume
+2.01% +2.59% +0.81% +1.55% -0.53% Change
More quotes
Financials (USD)
Sales 2019 7 654 M
EBIT 2019 2 327 M
Net income 2019 1 970 M
Finance 2019 6 158 M
Yield 2019 -
Sales 2020 8 186 M
EBIT 2020 2 907 M
Net income 2020 2 460 M
Finance 2020 7 635 M
Yield 2020 -
P/E ratio 2019 17,8x
P/E ratio 2020 14,5x
EV / Sales2019 3,54x
EV / Sales2020 3,13x
Capitalization 33 245 M
More Financials
Company
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows: - sales of products (61.2%); - supply of collaborative services (32.6%): working with Sanofi... 
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
10/10REGENERON PHARMACEUTICALS : to Report Third Quarter 2019 Financial and Operating..
PR
09/23REGENERON PHARMACEUTICALS : CHMP Recommends Approval of Dupixent for Severe Chro..
AQ
09/23REGENERON PHARMACEUTICALS : Lancet Publishes Results from Two Positive Phase 3 T..
AQ
09/23SANOFI : - CHMP recommends approval of Dupixent for severe chronic rhinosinusiti..
AQ
09/20REGENERON PHARMACEUTICALS : The Lancet Publishes Results from Two Positive Phase..
PU
09/20REGENERON PHARMACEUTICALS : Sanofi Get Positive CHMP Opinion for Dupixent
DJ
09/20REGENERON PHARMACEUTICALS : CHMP Recommends Approval of Dupixent® (dupilumab) fo..
PR
09/19Animal health sector aims to emulate Zoetis biotech leap
RE
09/18REGENERON PHARMACEUTICALS : Educational Campaign Helps Teens and Their Caregiver..
PR
09/17REGENERON PHARMACEUTICALS : Debuts on Prestigious Dow Jones Sustainability World..
PR
09/06REGENERON PHARMACEUTICALS : U.S. Court Dismisses Novartis Patent Infringement Su..
PU
08/29REGENERON PHARMACEUTICALS : U.S. District Court Invalidates Amgen Patent Claims ..
AQ
08/29GLOBAL MARKETS LIVE : Dell, United Airlines, UBS, Apple…
08/28U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight
RE
08/28REGENERON PHARMACEUTICALS : U.S. District Court Invalidates Amgen Patent Claims ..
PR
More news
News in other languages on REGENERON PHARMACEUTICALS
10/08Novartis obtient un feu vert outre-Atlantique contre la dégénérescence macula..
10/08US-Arzneimittelbehörde lässt neues Novartis-Augenmedikament zu
09/20Auf den Hund gekommen - Biotecharzneien für Haustiere auf dem Vormarsch
08/29EN DIRECT DES MARCHES : Pernod Ricard, Bouygues, Eurofins, Orange, MedinCell,..
08/29STOCK MARKET PARIS : Les marchés actions toujours dans le brouillard
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Sector news : Bio Therapeutic Drugs
07:52aINCYTE : Says Phase 3 REACH2 Trial Meets Endpoint
DJ
10/15New Gilead Sciences CFO Expected to Pursue More Deals to Expand Portfolio
DJ
10/15GILEAD SCIENCES : Names Andrew Dickinson Chief Financial Officer
DJ
10/10GILEAD SCIENCES : Galapagos See Efficacy in Advanced Rheumatoid Arthritis Study
DJ
10/10Snakes and ladders - SoftBank Vision Fund's climbing, sliding valuations
RE
More sector news : Bio Therapeutic Drugs
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 378,57  $
Last Close Price 303,82  $
Spread / Highest target 63,3%
Spread / Average Target 24,6%
Spread / Lowest Target 1,70%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Executive VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-18.66%33 245
GILEAD SCIENCES4.40%82 700
VERTEX PHARMACEUTICALS4.76%45 274
WUXI APPTEC CO., LTD.64.57%20 149
GENMAB30.26%13 356
NEUROCRINE BIOSCIENCES, INC.30.92%8 562